Leslie A. Royds Draper

Array ( [id] => 15990193 [patent_doc_number] => 20200170967 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-04 [patent_title] => MITORIBOSCINS: MITOCHONDRIAL-BASED THERAPEUTICS TARGETING CANCER CELLS, BACTERIA AND PATHOGENIC YEAST [patent_app_type] => utility [patent_app_number] => 16/670326 [patent_app_country] => US [patent_app_date] => 2019-10-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7386 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 94 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16670326 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15990193 [patent_doc_number] => 20200170967 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-04 [patent_title] => MITORIBOSCINS: MITOCHONDRIAL-BASED THERAPEUTICS TARGETING CANCER CELLS, BACTERIA AND PATHOGENIC YEAST [patent_app_type] => utility [patent_app_number] => 16/670326 [patent_app_country] => US [patent_app_date] => 2019-10-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7386 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 94 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16670326 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17679980 [patent_doc_number] => 11364210 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-06-21 [patent_title] => Mitoriboscins: mitochondrial-based therapeutics targeting cancer cells, bacteria and pathogenic yeast [patent_app_type] => utility [patent_app_number] => 16/670443 [patent_app_country] => US [patent_app_date] => 2019-10-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 26 [patent_no_of_words] => 7259 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 52 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16670443 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17200053 [patent_doc_number] => 20210340148 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-04 [patent_title] => PYRROLO-PYRIDAZINE DERIVATIVES AS MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS [patent_app_type] => utility [patent_app_number] => 17/285432 [patent_app_country] => US [patent_app_date] => 2019-10-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13011 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17285432 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15553345 [patent_doc_number] => 20200061084 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-27 [patent_title] => USE OF 2AMD AND 2MD TO TREAT FIBROSIS [patent_app_type] => utility [patent_app_number] => 16/592458 [patent_app_country] => US [patent_app_date] => 2019-10-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9073 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16592458 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17213023 [patent_doc_number] => 20210346359 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-11 [patent_title] => Use of CFTR Modulators For Treating Cerebrovascular Conditions [patent_app_type] => utility [patent_app_number] => 17/274726 [patent_app_country] => US [patent_app_date] => 2019-09-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14667 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17274726 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15586259 [patent_doc_number] => 20200069664 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-05 [patent_title] => METHODS FOR TREATING INFECTION [patent_app_type] => utility [patent_app_number] => 16/561525 [patent_app_country] => US [patent_app_date] => 2019-09-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14382 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16561525 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17473929 [patent_doc_number] => 20220081433 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-17 [patent_title] => CYCLIC SULFAMIDE COMPOUNDS FOR TREATMENT OF HBV [patent_app_type] => utility [patent_app_number] => 17/274058 [patent_app_country] => US [patent_app_date] => 2019-09-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19450 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 283 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17274058 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17967026 [patent_doc_number] => 11484531 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-11-01 [patent_title] => Methods for treating chronic obstructive pulmonary disease [patent_app_type] => utility [patent_app_number] => 16/555216 [patent_app_country] => US [patent_app_date] => 2019-08-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5313 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 90 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16555216 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17213031 [patent_doc_number] => 20210346367 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-11 [patent_title] => O-GLCNAC TRANSFERASE INHIBITORS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/271793 [patent_app_country] => US [patent_app_date] => 2019-08-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39828 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -55 [patent_words_short_claim] => 274 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17271793 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15432285 [patent_doc_number] => 20200030325 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-30 [patent_title] => Reverse Amide Compounds As Protein Deacetylase Inhibitors And Methods Of Use Thereof [patent_app_type] => utility [patent_app_number] => 16/550763 [patent_app_country] => US [patent_app_date] => 2019-08-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20800 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16550763 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15206179 [patent_doc_number] => 20190365776 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-05 [patent_title] => THERAPEUTIC AGENT FOR OCULAR FUNDUS DISEASE [patent_app_type] => utility [patent_app_number] => 16/542461 [patent_app_country] => US [patent_app_date] => 2019-08-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6232 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16542461 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15209703 [patent_doc_number] => 20190367538 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-05 [patent_title] => BORON-CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS [patent_app_type] => utility [patent_app_number] => 16/542748 [patent_app_country] => US [patent_app_date] => 2019-08-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15922 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -2 [patent_words_short_claim] => 12 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16542748 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17441776 [patent_doc_number] => 20220062281 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-03 [patent_title] => INHIBITORS TO TARGET HIV-1 NEF-CD80/CD86 INTERACTIONS FOR THERAPEUTIC INTERVENTION [patent_app_type] => utility [patent_app_number] => 17/268440 [patent_app_country] => US [patent_app_date] => 2019-08-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18986 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17268440 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17593412 [patent_doc_number] => 20220142985 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-12 [patent_title] => AGENTS FOR TREATMENT OF ALCOHOL USE DISORDER [patent_app_type] => utility [patent_app_number] => 17/267418 [patent_app_country] => US [patent_app_date] => 2019-08-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7014 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 68 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17267418 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17118722 [patent_doc_number] => 11129831 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-09-28 [patent_title] => Identification of agents displaying functional activation of dopamine D2 and D4 receptors [patent_app_type] => utility [patent_app_number] => 16/537193 [patent_app_country] => US [patent_app_date] => 2019-08-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 6786 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 71 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16537193 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15083325 [patent_doc_number] => 20190336473 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-07 [patent_title] => METHOD FOR TREATING CANCER WITH A COMBINATION OF QUERCETIN AND A CHEMOTHERAPY AGENT [patent_app_type] => utility [patent_app_number] => 16/511620 [patent_app_country] => US [patent_app_date] => 2019-07-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4122 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16511620 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15116947 [patent_doc_number] => 20190345106 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-14 [patent_title] => SALTS OF AN LSD1 INHIBITOR [patent_app_type] => utility [patent_app_number] => 16/447841 [patent_app_country] => US [patent_app_date] => 2019-06-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31659 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -50 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16447841 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14864801 [patent_doc_number] => 20190282642 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-19 [patent_title] => Method of Producing Cannabidiol Derived Products [patent_app_type] => utility [patent_app_number] => 16/428179 [patent_app_country] => US [patent_app_date] => 2019-05-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4241 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 88 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16428179 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16695457 [patent_doc_number] => 10946026 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-03-16 [patent_title] => Pharmaceutical compositions and methods for treating mental, behavioral, cognitive disorders [patent_app_type] => utility [patent_app_number] => 16/424788 [patent_app_country] => US [patent_app_date] => 2019-05-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6289 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16424788 [rel_patent_id] =>[rel_patent_doc_number] =>)